# BUILD 3: Bosentan Use in Interstitial Lung Disease

> **NCT00391443** · PHASE3 · COMPLETED · sponsor: **Actelion** · enrollment: 616 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Bosentan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00391443
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2010-02
- **Final completion:** 2010-07
- **Target enrollment:** 616 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00391443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00391443, "BUILD 3: Bosentan Use in Interstitial Lung Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00391443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*